牛牛AI助理已提取核心訊息
On January 9, 2024, Avenue Therapeutics, Inc. reported a significant corporate action through a Form 8-K filing with the SEC. The company's shareholders approved an increase in authorized common stock from 75 million to 200 million shares. This increase, known as the Authorized Share Increase, was formalized by an amendment to the company's Third Amended and Restated Certificate of Incorporation filed with the Delaware Secretary of State. Additionally, shareholders authorized the issuance of shares underlying warrants that could exceed 20% of the pre-issuance outstanding common stock, in compliance with Nasdaq Listing Rule 5635(d). These warrants were part of inducement letter agreements dated January 5, 2024. The consent for these actions was provided by holders of a majority of the voting power, representing approximately 56.4% of the capital stock as of the consent date. The company's Board of Directors also approved these measures. A Schedule 14C information statement will be distributed to shareholders, as required by SEC rules.
On January 9, 2024, Avenue Therapeutics, Inc. reported a significant corporate action through a Form 8-K filing with the SEC. The company's shareholders approved an increase in authorized common stock from 75 million to 200 million shares. This increase, known as the Authorized Share Increase, was formalized by an amendment to the company's Third Amended and Restated Certificate of Incorporation filed with the Delaware Secretary of State. Additionally, shareholders authorized the issuance of shares underlying warrants that could exceed 20% of the pre-issuance outstanding common stock, in compliance with Nasdaq Listing Rule 5635(d). These warrants were part of inducement letter agreements dated January 5, 2024. The consent for these actions was provided by holders of a majority of the voting power, representing approximately 56.4% of the capital stock as of the consent date. The company's Board of Directors also approved these measures. A Schedule 14C information statement will be distributed to shareholders, as required by SEC rules.
2024年1月9日，Avenue Therapeutics, Inc.通過向美國證券交易委員會提交的8-K表格報告了一項重大公司行動。該公司的股東批准將授權普通股從7500萬股增加到2億股。此次增持被稱爲授權增股，是通過對該公司向特拉華州國務卿提交的第三次修訂和重述的公司註冊證書的修正案正式確定的。此外，根據納斯達克上市規則5635（d），股東授權發行可能超過發行前已發行普通股20％的股票標的認股權證。這些認股權證是2024年1月5日的激勵信協議的一部分。這些行動的同意是由大多數投票權的持有人提供的，截至同意之日約佔股本的56.4％。公司董事會也批准了這些措施。根據美國證券交易委員會規則的要求，附表14C的信息聲明將分發給股東。
2024年1月9日，Avenue Therapeutics, Inc.通過向美國證券交易委員會提交的8-K表格報告了一項重大公司行動。該公司的股東批准將授權普通股從7500萬股增加到2億股。此次增持被稱爲授權增股，是通過對該公司向特拉華州國務卿提交的第三次修訂和重述的公司註冊證書的修正案正式確定的。此外，根據納斯達克上市規則5635（d），股東授權發行可能超過發行前已發行普通股20％的股票標的認股權證。這些認股權證是2024年1月5日的激勵信協議的一部分。這些行動的同意是由大多數投票權的持有人提供的，截至同意之日約佔股本的56.4％。公司董事會也批准了這些措施。根據美國證券交易委員會規則的要求，附表14C的信息聲明將分發給股東。
有用
沒用